$AKAO Key Players - $9.89 BN by 2023 Big players in the global urinary tract infection (UTI) market include AstraZeneca (UK), Bayer AG (Germany), Cipla Inc. (India), Dr. Reddy’s Laboratories Ltd. (India), GlaxoSmithKline (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Johnson & Johnson (USA), Novartis AG (Switzerland), and Pfizer Inc. (USA). A new report on the global urinary tract infection (UTI) market, published by Market Research Future (MRFR), assays that this market could notice a hike at 3.6% CAGR between 2019 and 2023. In terms of money value, the market can be worth USD 9.89 Bn by the end of the forecast period. Lead by the USA; North America holds the maximum market share in the global market followed by Europe. This projection of Cipla as a "Big Player" is due to/based on their Zemdri license in the U.S. 30min IV has STRONG application in the outpatient market.. in this patient group. EOS